Clinical Consultations™: Redefining Dry Eye Disease - Focusing on the Tear Film: Stability, Diagnosis, Homeostasis, & COVID-19 Considerations in DED

Released On
July 13, 2021

Expires On
July 13, 2022

Media Type

Completion Time
90 minutes

Ophthalmology, Primary Care

Eye Disorders, Pharmacology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grant from Oyster Point Pharma

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours
  • Optometrists - 1.5 COPE Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward ophthalmologists and optometrists who care for patients affected by dry eye disease (DED). Other health care providers involved in the care of patients with DED are also invited to participate.

Activity Overview

Dry eye disease (DED) affects about 7% of the US population, and if left untreated, can affect vision and negatively impact quality of life. Eye care experts in DED have recently developed a new definition of DED intended for use worldwide and aimed at providing eye care professionals with a practical tool to help diagnose DED precisely and consistently, using devices already available in the clinic. In this program, two ophthalmologists who specialize in DED review the increasing prevalence of this disease in the digital era and examine the impact of COVID-19 and mask-wearing on its incidence. They also discuss steps in the diagnosis of DED, available and emerging therapies, both devices and pharmacologic agents, and provide expert advice on selecting treatment and counseling patients diagnosed with DED.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the role of tear film stability within dry eye disease pathophysiology, diagnosis, and as a target for treatment options
  • Evaluate mechanisms, efficacy, and safety data for emerging mechanical and pharmacological treatments which target tear film homeostasis
  • Recognize the impact of increased digital device use to the COVID-19 pandemic on the prevalence of DED
  • Assess the impact COVID-19 may have on visitations to the clinic by reluctant patients and appropriate permissions for pharmaceutical representative appointments



Cynthia Matossian, MD, FACS

Medical Director, Matossian Eye Associates
Adjunct Clinical Instructor
Department of Ophthalmology
Temple University School of Medicine
Philadelphia, PA


Stephen C. Pflugfelder, MD

Professor, Department of Ophthalmology
Baylor College of Medicine
Houston, TX


Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Optometrist Continuing Education

This activity, COPE Activity Number 122046, is accredited by COPE for continuing education for optometrists.

Disclosures of Conflicts of Interest

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Cynthia Matossian, MD, FACS

  • Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Aramis Biosciences, Bausch + Lomb, Bruder Healthcare, CheckedUp, Conclusn, Dompé, EyePoint, Eyevance, Glint Pharmaceuticals, Guardion Health Services, Imprimis Pharmaceuticals, Johnson & Johnson, Kala Pharmaceuticals, LacriScience, Legrande Health, Lenstec, Lumenis, Marco, MDbackline, Novartis, NuSight Medical, Ocular Science, Olympic Ophthalmics, Omeros, Osmotica Pharmaceuticals, Physician Recommended Nutriceuticals, Quidel, Regener-Eyes, StepWise Medical, Sun Pharmaceutical Industries, TearLab, TearScience (J&J), TissueTech, Visionology, Visus Therapeutics, Zeiss
  • Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, EyePoint, Eyevance, Guardion Health Services, Imprimis Pharmaceuticals, Johnson & Johnson, Kala Pharmaceuticals, LacriScience Vision, Lumenis, Novartis, NuSight Medical, Olympic Ophthalmics, Omeros, Physician Recommended Nutriceuticals, Sun Pharmaceutical Industries, TearLab, TearScience, TissueTech, Zeiss
  • Research Funding: Dompé, Imprimis Pharmaceuticals, Johnson & Johnson, Novartis
  • Investor: CheckedUp, Physician Recommended Nutriceuticals, Strathspey Crown, Veterinarian Recommended Solutions


Stephen C. Pflugfelder, MD

  • Grant/Research Support: Dompé
  • Consultant: Kala Pharmaceuticals, Dompé, Novartis, Kowa, Senju Pharmaceutical

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.